Skip to main content
Clinical Trials/NCT04698174
NCT04698174
Completed
N/A

Prospective Clinical Study to Evaluate the Safety and Efficacy of a New Transepithelial Photorefractive Keratectomy Treatment

Bausch & Lomb Incorporated1 site in 1 country39 target enrollmentFebruary 2, 2021
ConditionsAmetropia

Overview

Phase
N/A
Intervention
Not specified
Conditions
Ametropia
Sponsor
Bausch & Lomb Incorporated
Enrollment
39
Locations
1
Primary Endpoint
Absolute refractive predictability
Status
Completed
Last Updated
3 years ago

Overview

Brief Summary

This is a prospective, comparative, randomized, controlled, single-blind, single-surgeon, single-center PMCF clinical study whereby participants undergoing refractive surgery for correction of ametropia will receive a transepithelial PRK (tPRK) and conventional PRK treatment in the contralateral eye. To avoid bias in the clinical outcomes, the two PRK treatment options are randomized to the eyes of the patients based on ocular dominance. In addition, a 1:1 randomization is applied within the tPRK group to eyes with and without end-treatment laser polishing.

Both procedures, standard PRK and tPRK, are performed in a one-step procedure. The main difference between the procedures is, that in conventional PRK, the epithelium will be removed using alcohol, whereas in tPRK procedures, the epithelium will be removed by laser ablation.

Registry
clinicaltrials.gov
Start Date
February 2, 2021
End Date
March 21, 2022
Last Updated
3 years ago
Study Type
Interventional
Study Design
Parallel
Sex
All

Investigators

Responsible Party
Sponsor

Eligibility Criteria

Inclusion Criteria

  • Ametropia
  • Myopic subjects with refractive spherical equivalent (MRSE) between -1.5D and -9.0D
  • Hyperopic subjects with refractive spherical equivalent (MRSE) between +1.5D and +5.25D
  • Signed informed consent form

Exclusion Criteria

  • Ocular comorbidity
  • Subject taking systemic medications likely to affect wound healing such as corticosteroids or antimetabolites.
  • Subjects who are known to be pregnant, lactating, or who plans to become pregnant over the medications used for standard tPRK.
  • Subjects participating in any other ophthalmic clinical trial during this clinical study.
  • Subjects with cognitive impairments or other vulnerable persons

Outcomes

Primary Outcomes

Absolute refractive predictability

Time Frame: 3 months follow up

Absolute refractive predictability is the absolute difference between intended and achieved Manifest Refraction Spherical Equivalent (MRSE) between eyes

Secondary Outcomes

  • Monocular Corrected Distance Visual Acuity (CDVA) under photopic light conditions(3 months follow up)
  • Monocular Uncorrected Distance Visual Acuity (UDVA) under mesopic light conditions(3 months follow up)
  • Monocular Corrected Distance Visual Acuity (CDVA) under mesopic light conditions(3 months follow up)
  • Monocular Uncorrected Distance Visual Acuity (UDVA) under photopic light conditions(3 months follow up)
  • Halo Photic phenomena(3 months follow up)
  • Glare Photic phenomena(3 months follow up)
  • Monocular Contrast Sensitivity(3 months follow up)
  • Visual perception scale(3 months follow up)
  • Corneal pain(3 months follow up)

Study Sites (1)

Loading locations...

Similar Trials